Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Liabilities-to-Assets is a solvency ratio indicating how much of the company’s assets are made of liabilities, calculated as total liabilities divided by total asset. Medclair AB's Total Liabilities for the quarter that ended in Mar. 2026 was kr10.32 Mil. Medclair AB's Total Assets for the quarter that ended in Mar. 2026 was kr89.49 Mil.
Therefore, Medclair AB's Liabilities-to-Assets Ratio for the quarter that ended in Mar. 2026 was 0.12.
Medclair AB (NGM:MCLR) Liabilities-to-Assets Explanation
Liabilities-to-Assets is a solvency ratio indicating how much of the company’s assets are made of liabilities. It can vary greatly across different industries, as they have different capital structure. A high Liabilities-to-Assets ratio (more leveraged) suggests that the company might have potential solvency problems, or even a signal of financial distress. Conversely, a low Liabilities-to-Assets ratio usually indicates a healthy financial situation. However, it may also suggest that the company is not expanding or not making good use of debt.
Medclair AB Liabilities-to-Assets Related Terms
Medclair AB Liabilities-to-Assets Historical Data
* Premium members only.
The historical data trend for Medclair AB's Liabilities-to-Assets can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NGM:MCLR vs ABT, SYK, MDT: Liabilities-to-Assets Comparison
For the Medical Devices subindustry, Medclair AB's Liabilities-to-Assets, along with its competitors' market caps and Liabilities-to-Assets data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Medclair AB Liabilities-to-Assets vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Medclair AB's Liabilities-to-Assets distribution charts can be found below:
* The bar in red indicates where Medclair AB's Liabilities-to-Assets falls into.
Liabilities-to-Assets ratio measures the portion of the total liabilities to the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.
Liabilities-to-Assets ratio is calculated by dividing total liabilities by total asset.
Medclair AB's Liabilities-to-Assets Ratio for the fiscal year that ended in Dec. 2025 is calculated as:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Medclair AB (NGM:MCLR) has a Liabilities-to-Assets of 0.12 as of Mar. 2026. Liabilities-to-Assets equals total liabilities divided by total assets. It measures financial leverage. View historical data on Medclair AB and its competitors.
Is Medclair AB's Liabilities-to-Assets too high?
Medclair AB's current Liabilities-to-Assets is 0.12. Overall, Medclair AB has a GF Score™ of 75/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Medclair AB's Liabilities-to-Assets compare to ABT and SYK?
Medclair AB's Liabilities-to-Assets of 0.12 can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Liabilities-to-Assets for a Medical Devices & Instruments company?
A good Liabilities-to-Assets depends on the Medical Devices & Instruments industry context. However, Liabilities-to-Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Liabilities-to-Assets mean?
A high Liabilities-to-Assets can signal that a stock is expensive relative to its fundamentals. Liabilities-to-Assets equals total liabilities divided by total assets. It measures financial leverage. View historical data on Medclair AB and its competitors. Medclair AB's current Liabilities-to-Assets is 0.12. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Medclair AB stock overvalued right now?
Based on GuruFocus' analysis, Medclair AB (NGM:MCLR) is currently considered Modestly Overvalued. The stock's GF Value™ is kr2.38, compared to a current price of kr2.80 — trading 17.6% above its estimated fair value. The current Liabilities-to-Assets is 0.12. Medclair AB's overall GF Score™ is 75/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Liabilities-to-Assets calculated?
Liabilities-to-Assets is calculated from a company's financial statements. For Medclair AB (NGM:MCLR), the current Liabilities-to-Assets is 0.12 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Medclair AB (NGM:MCLR) Overvalued in 2026?
Based on GuruFocus' analysis, Medclair AB stock appears to be overvalued.
The current stock price of kr2.80 is trading 17.6% above its estimated GF Value™ of kr2.38.
GuruFocus considers Medclair AB to be Modestly Overvalued.
Key valuation signals for NGM:MCLR:
Liabilities-to-Assets: 0.12
GF Value™: kr2.38 vs. price of kr2.80 (17.6% above fair value)
No single metric tells the full story. See the NGM:MCLR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Medclair AB operates in healthcare industry. The company has two units: Central Destruction Unit (CDU) and Mobile Destruction Unit (MDU) decomposes the nitrous oxide entering the unit, transforming it to nitrogen (N2) och oxygen (O2). It also provide solutions for various N2O methods such as double mask, single mask, mouthpiece, or free flow, which ensures a safe work environment for healthcare professionals.
75GF Score
Get the complete analysis for NGM:MCLR
Liabilities-to-Assets is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NGM:MCLR has been successfully added to your 
